findmyKOL
Clinical trialNCT00529399CompletedPhase 2Interventional

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrollment145Type 1 Diabetes Mellitus
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes mellitus (T1DM).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Hospital for Sick Children

    Toronto, Ontario, Canada

United States
  • Childrens Hospital of Los Angeles

    Los Angeles, California, United States

  • Stanford University

    Palo Alto, California, United States

  • University of California-San Francisco

    San Francisco, California, United States

  • Barbara Davis Center for Childhood Diabetes/university of Colorado Health Sciences Center

    Aurora, Colorado, United States

  • Yale University School of Medicine

    New Haven, Connecticut, United States

  • University of Florida

    Gainesville, Florida, United States

  • University of Miami/ Miller School of Medicine

    Miami, Florida, United States

  • Indiana University School of Medicine

    Indianapolis, Indiana, United States

  • Joslin Diabetes Center

    Boston, Massachusetts, United States

  • University of Minnesota

    Minneapolis, Minnesota, United States

  • Columbia University

    New York, New York, United States

  • Childrens Hospital of Pittsburgh

    Pittsburgh, Pennsylvania, United States

  • University of Texas/southwestern Medical School

    Dallas, Texas, United States

  • Benaroya Research Institute

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aluminum hydroxideGAD-AlumGAD-Alum and Aluminum hydroxide
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Feb 2009
Primary completion
31 May 2012
Completion
31 May 2012
Last update posted
7 May 2020
Registered enrollment
145
Registry id
NCT00529399
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.